Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion

Secukinumab, an interleukin (IL)-17A antagonist, was associated with disease exacerbations in Crohn’s disease, and de novo cases of inflammatory bowel disease (IBD) have been reported in studies of rheumatoid diseases. However, there has been no detailed report demonstrating the linkage between secu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ACG Case Rep J
Autors principals: Wang, Jingzhou, Bhatia, Arvin, Krugliak Cleveland, Noa, Gupta, Nina, Dalal, Sushila, Rubin, David T., Sakuraba, Atsushi
Format: Artigo
Idioma:Inglês
Publicat: American College of Gastroenterology 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6072803/
https://ncbi.nlm.nih.gov/pubmed/30105273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14309/crj.2018.56
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars